Mounjaro in Wales: what the NHS offers and how private treatment works

The misconception: NICE recommended it, so it must be available on the NHS in Wales

The most common misunderstanding is this: NICE recommended Mounjaro in December 2024 (TA1026), therefore it should be available on the Welsh NHS. That is not quite how it works. NICE guidance applies directly to NHS England; NHS Wales is governed by the All Wales Medicines Strategy Group (AWMSG), which makes its own appraisal decisions. Until AWMSG issues a positive recommendation and NHS Wales funds it through its Local Health Boards, Mounjaro sits outside routine NHS prescribing in Wales. That gap can be months or years wide.

Scotland and Northern Ireland are in a similar position, devolved health systems mean devolved timelines. If you live in Cardiff, Swansea, Wrexham or anywhere else in Wales and you have been told "just ask your GP", it is worth understanding that most Welsh GPs do not currently have a funded pathway to prescribe Mounjaro for weight management. Some patients do receive it through specialist obesity services, but those referrals take time and waiting lists are long.

The practical upshot: private treatment through a regulated pharmacy is, for now, the realistic option for most people in Wales who want to start tirzepatide. You can read a fuller picture of how tirzepatide works as a medicine before deciding whether to pursue that route.

Who can access Mounjaro privately in Wales, and what the prescriber looks at

The licensed eligibility criteria are set by the medicine's UK marketing authorisation, not by your postcode. A private prescriber in Wales follows the same SmPC criteria as one in Manchester: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, obstructive sleep apnoea, high cholesterol or cardiovascular disease. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

Those numbers are a starting point, not a guarantee. A prescriber also considers your full medical history, any medicines you take, contraindications and whether treatment is appropriate for you as an individual. Pregnancy, breastfeeding, or trying to conceive rules out treatment; so does a history of medullary thyroid carcinoma or certain other conditions. Under-18s are not eligible under the UK licence.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not a questionnaire scored by software. If you order before noon on a weekday, your answers reach a prescriber's desk the same day. Approved patients have their treatment dispatched the same afternoon, arriving with DPD the next working day in plain packaging. There are no subscription commitments; every repeat order is reviewed clinically again from scratch.

If you want to check what the prescribing criteria look like in practice, the guide to getting a Mounjaro prescription in the UK covers the full process step by step.

What clinical trials showed, and what Wales-specific data exists

There are no Wales-specific trial results for Mounjaro; the evidence base is the global SURMOUNT programme. SURMOUNT-1, published in the New England Journal of Medicine, involved 2,539 adults with obesity across multiple countries. At the 15mg maintenance dose over 72 weeks, participants lost around 20 to 21% of body weight on average. In the SURMOUNT-5 trial, published in 2025, tirzepatide outperformed semaglutide 2.4mg head-to-head over 72 weeks in adults with obesity but without diabetes. NICE's appraisal of tirzepatide (TA1026) drew on this evidence base when making its recommendation to NHS England.

It is worth being honest about what those figures mean in practice. Trial participants follow structured programmes, see clinical teams regularly and take part under controlled conditions. Real-world results vary. That is precisely why ongoing clinical oversight (checking in, reviewing your progress, adjusting doses) matters as much as the medicine itself.

People in Wales sometimes ask whether Mounjaro is the same as Ozempic. It is not. Ozempic is semaglutide, licensed in the UK for type 2 diabetes rather than weight management. Mounjaro works on two gut-hormone receptors (GIP and GLP-1) rather than one, which is part of why the trial figures differ. The full Mounjaro overview explains the mechanism in plain terms if you want the detail.

Cost context and what to watch out for when buying online from Wales

Private Mounjaro is priced per four-week pen, and costs have shifted considerably since Eli Lilly raised its UK list price in September 2025. Reported private prices since then range roughly £149 to £375 per month depending on the dose and provider, something explored in more detail on the Mounjaro sales and pricing context page. The right question for any provider is not just "how much is the pen?" but what is included: prescription fee, clinical review, delivery and aftercare support all have a cost somewhere, even if it is hidden.

The MHRA has issued repeated warnings about fake weight-loss pens sold online, including a counterfeit tirzepatide operation raided in England in October 2025. Those concerns extend to the broader market, which our overview of tirzepatide sales in the UK examines alongside what to look for in a legitimate provider. The red flags are consistent: sellers who will supply a prescription medicine without a prior consultation, prices significantly below the market range, or social-media accounts with no verifiable pharmacy registration. Any legitimate online pharmacy dispensing Mounjaro must be registered with the GPhC, you can check any pharmacy's registration directly at the GPhC pharmacy register. If you cannot verify it there, do not order from it.

If cost is a concern, it is also worth reading about what the evidence says about how Mounjaro produces weight loss, understanding the mechanism helps set realistic expectations alongside treatment. And if you are curious about the team behind the clinical reviews at nume, our clinical lead's profile sets out our prescribing approach. When you are ready to see whether treatment is suitable for you, checking your eligibility is the logical next step.